Search Articles and Web Sources

Search Results

In this project

Breakthrough in Parkinson's Disease Treatment: JOTROL US Trials

https://sudonull.com/breakthrough-in-parkinson-s-disease-treatment-jotrol-us-trials

Critical Analysis of Jupiter Neurosciences' Phase 2a JOTROL: Bioavailability, Finances, Supplements, and Hidden Risks. Read Before Believing the Breakthrough.

Chinese exoskeleton 0.96 kg: treatment of muscle atrophy from Nature

https://sudonull.com/chinese-exoskeleton-0-96-kg-treatment-of-muscle-atrophy-from-nature

Chinese exoskeleton weighing 0.96 kg treats muscular dystrophy, not replaces function. Nature results: children stood up without the device. Find out how this changes the market.

Replacement of Gold Nanoparticles for Laser Cancer Treatment in Russia

https://sudonull.com/replacement-of-gold-nanoparticles-for-laser-cancer-treatment-in-russia

Russian scientists replaced expensive gold with tungsten and palladium diselenides for photothermal cancer therapy. Learn about a cheap and safe method for destroying inoperable tumors.

Competition in brain models improves therapy accuracy

https://sudonull.com/competition-in-brain-models-improves-therapy-accuracy

Digital brain twins taking into account zone competition increase prediction accuracy for medicine. Learn how this changes epilepsy treatment and AI developments. Read the analysis of principles and consequences.

AI-driven phage therapy: Locus Biosciences clinical trials

https://sudonull.com/ai-driven-phage-therapy-locus-biosciences-clinical-trials

Breakthrough in superbug treatment: Locus Biosciences automated phage therapy with AI and CRISPR-Cas3 moves to clinical trials. Learn about the revolution in biopharmaceuticals.

From other projects

Digital atlas of the liver: 8 zones instead of 3

https://ymaho.com/digital-atlas-of-the-liver-8-zones-instead-of-3

The first digital atlas of the liver revealed 8 functional zones, not 3. Learn how this discovery is changing the treatment of liver diseases and the hepatology market. Read the details!

Universal CAR-T therapy: FDA allows trials for autoimmune diseases

https://ymaho.com/universal-car-t-therapy-fda-allows-trials-for-autoimmune-diseases

FDA approved clinical trials of allogeneic CAR-T cell therapy QT-019C for lupus and scleroderma. Savings up to $100 billion, no chemotherapy. Learn about the breakthrough.

Vyjuvek gene gel treatment butterfly disease DEB 2026

https://ymaho.com/vyjuvek-gene-gel-treatment-butterfly-disease-deb-2026

UK approves Vyjuvek gene gel for wound treatment in dystrophic epidermolysis bullosa. Efficacy 67% at 6 months. Learn mechanism of action and prospects.

Digital atlas of the liver: 8 zones instead of 3 — a breakthrough in hepatology

https://ymaho.com/digital-atlas-of-the-liver-8-zones-instead-of-3-a-breakthrough-in-hepatology

Nature published the first digital atlas of the human liver with 2-micron resolution. Find out why this changes the treatment of fatty liver disease and the paradigm of hepatology.

Auvelity for dementia: FDA approved alternative to antipsychotics

https://ymaho.com/auvelity-for-dementia-fda-approved-alternative-to-antipsychotics

FDA approved Auvelity for the treatment of agitation in Alzheimer's disease. First non-antipsychotic agent without mortality risk. Learn about the new standard of therapy.

Gene therapy OPGx-LCA5 accepted into FDA RDEP program

https://ymaho.com/gene-therapy-opgx-lca5-accepted-into-fda-rdep-program

Learn how Opus Genetics' gene therapy OPGx-LCA5 received RDEP status from the FDA, accelerating the development of treatment for ultra-rare LCA5 blindness in children. Detailed analysis and prospects.

Mesenchymal drift: a new mechanism of aging and Alzheimer's treatment

https://ymaho.com/mesenchymal-drift-a-new-mechanism-of-aging-and-alzheimer-s-treatment

Discovery of mesenchymal drift — key to cell rejuvenation. A clinical trial for Alzheimer's disease treatment starts with 240 patients. Learn more.

A New Look at Alzheimer's Disease: Roche Tests Spinal ASO Therapy

https://ymaho.com/a-new-look-at-alzheimer-s-disease-roche-tests-spinal-aso-therapy

Roche has initiated Phase I trials of intrathecal ASO against ApoE for early Alzheimer's disease. Why this is a revolution, who will benefit, and hidden risks. Read the analysis.

Vyvgart approved for all serotypes of myasthenia gravis

https://ymaho.com/vyvgart-approved-for-all-serotypes-of-myasthenia-gravis

FDA expanded Vyvgart indications to all patients with generalized myasthenia gravis. Learn how this will change the treatment market. Read analysis.

Mianserin: treatment of progeria increased lifespan

https://ymaho.com/mianserin-treatment-of-progeria-increased-lifespan

Nature Communications study: antidepressant mianserin restores calcium homeostasis and prolongs life in mice with progeria and aging mice. Learn about the S100A6 and cGAS-STING mechanism.